A suppressive effect of dexamethasone (DEX) on adrenocorticotropin (ACTH) response to vasoactive intestinal peptide (VIP) in Cushing's disease: a parallel modulation by DEX of ACTH responses to VIP and corticotropin-releasing hormone.

Watanobe H, Tamura T

Neuropeptides1 Feb 1997Cited by 2 (Europe PMC)

PMID9574835DOI10.1016/s0143-4179(97)90017-2PepBankPUB-09574835

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialOther
In 5 of 7 patients with Cushing's disease, dexamethasone pretreatment significantly suppressed the ACTH response to VIP.
In plain wordsIn 5 of 7 people with Cushing's disease, dexamethasone lowered the ACTH rise caused by a VIP dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseACTH response to VIP after dexamethasone in 5 responders
Study
n = 5
Comparator
No dexamethasone pretreatment
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
The results were that in 5 patients, DEX was able to significantly suppress the ACTH and cortisol responses to both CRH and VIP
1 context sentence(design, population, supporting numbers)
Summary · context
we examined whether this linkage also exists after glucocorticoid treatment by testing the effect of dexamethasone (DEX) pretreatment (1.0 mg, intravenous bolus, 60 min before) on ACTH and cortisol responses to CRH (100 microg, i.v. bolus)
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0957483501
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialOther
In 5 of 7 patients with Cushing's disease, dexamethasone pretreatment significantly suppressed the cortisol response to VIP.
In plain wordsIn 5 of 7 people with Cushing's disease, dexamethasone lowered the cortisol rise caused by a VIP dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseCortisol response to VIP after dexamethasone in 5 responders
Study
n = 5
Comparator
No dexamethasone pretreatment
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
The results were that in 5 patients, DEX was able to significantly suppress the ACTH and cortisol responses to both CRH and VIP
1 context sentence(design, population, supporting numbers)
Summary · context
we examined whether this linkage also exists after glucocorticoid treatment by testing the effect of dexamethasone (DEX) pretreatment (1.0 mg, intravenous bolus, 60 min before) on ACTH and cortisol responses to CRH (100 microg, i.v. bolus)
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0957483502
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialOther
In 2 of 7 patients with Cushing's disease, dexamethasone pretreatment did not significantly affect the response to VIP.
In plain wordsIn 2 of 7 people with Cushing's disease, dexamethasone did not change the response to a VIP dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeACTH and cortisol response to VIP after dexamethasone in 2 non-responders
Study
n = 2
Comparator
No dexamethasone pretreatment
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
and in the remaining 2 patients, DEX did not significantly affect the action of either CRH or VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
we examined whether this linkage also exists after glucocorticoid treatment by testing the effect of dexamethasone (DEX) pretreatment (1.0 mg, intravenous bolus, 60 min before) on ACTH and cortisol responses to CRH (100 microg, i.v. bolus)
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0957483503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.